GRAIL, Inc. (GRAL)
| Market Cap | 2.86B +101.9% |
| Revenue (ttm) | 156.12M +19.4% |
| Net Income | -395.33M |
| EPS | -10.31 |
| Shares Out | 42.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,276,435 |
| Open | 61.08 |
| Previous Close | 61.13 |
| Day's Range | 61.08 - 68.93 |
| 52-Week Range | 29.95 - 118.84 |
| Beta | 3.15 |
| Analysts | Buy |
| Price Target | 66.86 (+0.47%) |
| Earnings Date | May 5, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $66.86, which is an increase of 0.47% from the latest price.
News
Grail initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Grail (GRAL) with a Neutral rating and $60 price target While the company’s Galleri test has had success in penetrating the self-pay market for multi-cancer…
GRAIL Transcript: Jefferies Global Healthcare Conference 2026
Recent results show strong volume and revenue growth, with major clinical studies demonstrating significant early-stage cancer detection and reduced late-stage incidence. Regulatory progress continues, with FDA review underway and expanded reimbursement expected to drive broader adoption and margin improvement.
Grail assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Grail (GRAL) with a Peer Perform rating and no price target The company need payor support to scale, says Wolfe, which prefers to monitor Grail’s…
GRAIL Transcript: Study result
Results from NHS-Galleri and PATHFINDER 2 trials show Galleri MCED testing significantly increases early cancer detection, reduces stage 4 and emergency-presenting cancers, and maintains high specificity and PPV. Most detected cancers lack current screening options, supporting broad clinical utility.
GRAIL Press release: Study result
GRAIL issued a press release on May 31, 2026, disclosing material business information to investors.
GRAIL Slides: Study result
GRAIL has posted slides in relation to its latest quarterly earnings report, which was published on May 31, 2026.
Grail presents ‘positive’ performance, safety results from Pathfinder 2 study
GRAIL (GRAL) announced that “positive” performance and safety results from the analysis of the full 35,878 cohort of its registrational Pathfinder 2 study are being presented during an oral session…
Grail reports results from NHS-Galleri trial in presentation at ASCO meeting
GRAIL (GRAL) announced detailed clinical utility, performance and safety results from its NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meet...
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers De...
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri ® Blood Test Reduced Stage IV...
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif., May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equi...
GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
MENLO PARK, Calif., May 26, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management ...
GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management ...
GRAIL Transcript: Bank of America Global Healthcare Conference 2026
Digital and traditional channels are driving strong self-pay growth, with over 1,300 new physicians added and high retest rates. Key clinical data from a large RCT will be presented at ASCO, while FDA and CMS reviews progress. Operational scale and cost efficiency position the business for broad access and future expansion.
Grail price target lowered to $70 from $82 at Baird
Baird lowered the firm’s price target on Grail (GRAL) to $70 from $82 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results. Published…
Grail price target raised to $56 from $54 at Piper Sandler
Piper Sandler raised the firm’s price target on Grail (GRAL) to $56 from $54 and keeps a Neutral rating on the shares. The firm notes the company delivered Q1 beat…
Grail price target raised to $69 from $65 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Grail (GRAL) to $69 from $65 and keeps a Buy rating on the shares. The firm said they posted…
Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking
Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo G...
Grail reports Q1 EPS ($2.29), consensus ($1.96)
Reports Q1 revenue $40.8M, consensus $39.15M. “GRAIL (GRAL) continues to execute commercially, with strong volume growth in Q1. We continue to build new partnerships to support demand and were pleased...
GRAIL Earnings Call Transcript: Q1 2026
Q1 2026 saw 50% test volume growth and 37% screening revenue growth, with strong adoption across providers and digital health. FDA review of Galleri is underway, Salesforce expansion is on track, and full-year revenue guidance is reiterated at 22–32%.
GRAIL Earnings release: Q1 2026
GRAIL released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
GRAIL Quarterly report: Q1 2026
GRAIL has published its Q1 2026 quarterly earnings report on May 5, 2026.
GRAIL Reports First Quarter 2026 Financial Results
Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platf...